Glaxo drug takes step forward
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.GLAXO, the pharmaceuticals giant, yesterday moved one step closer to achieving regulatory approval in the United States for the prescription of its anti-nausea drug Zofran for all patients suffering sickness after operations, writes Heather Connon.
An advisory committee of the US Food and Drug Administration recommended to the full board that Zofran, in injectable form, be given approval. This is a critical stage in the process of gaining permission to market the drug.
Zofran, again in injectable form, is already approved for the treatment of nausea in patients undergoing chemotherapy in the US. It is also seeking approval for the tablet form of the drug. The group estimates that 30 per cent of surgical procedures cause some vomiting.
Analysts expect Zofran to have sales of between pounds 260m and pounds 270m this year.
Glaxo is due to announce its profits for the year to June on Thursday and the City is expecting pre-tax profits to increase from pounds 1.28bn to about pounds 1.45bn.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments